Genome-wide CRISPR screens to identify new therapeutic targets and inhibit SARS-CoV-2 replication

Key facts

Disease
COVID-19
Funder
ANR
Principal Investigator
Caroline GOUJON
Research Location
France
Lead Research Institution
Institut de Recherche en Infectiologie de Montpellier (IRIM) ? CNRS
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

The CRISPR-TARGET-CoV project, coordinated by Caroline Goujou (UMR 9004 Institut de Recherche en Infectiologie de Montpellier (IRIM) - CNRS), aims to produce screens using CRISPR technology at the genome scale in order to identify cofactors and cellular SARS-CoV-2 inhibitors. He will then focus on screening molecules of interest selected for their relevance to the cellular factors identified. The effect of the best molecules will be validated ex vivo in a 3D system of primary respiratory targets of SARS-CoV-2.

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Development and Validation of the Intimate Partner Violence Workplace Disruptions Assessment (IPV-WDA).

Elucidating directed neural dynamics of scene construction across memory and imagination

Implementing a Novel Resident-Led Peer Support Program for Emergency Medicine Resident Physicians.

Cross-Activity Analysis of CRISPR/Cas9 Editing in Gene Families of <i>Solanum lycopersicum</i> Detected by Long-Read Sequencing.

Creating health systems citizens: enhanced professional identity formation through a para-curricular distinction track in health systems transformation and leadership.

A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer's Disease Continuum: A Systematic Review.